Thus, pharmacological inhibition of FAK activity with PF-271 or similar small molecule inhibitors will impact in Y658 VE-cadherin with important consequences in beta-catenin-derived TCF4/LEF activation of gene expression and may imply a new therapeutic opening in the overall repression of genes involved VM promotion in cancer cells. Here, CDH5 is linked to cancer.